Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. DE· CIK 0001159036

HALO

HALOZYME THERAPEUTICS, INC.
$109.34 ▲ +2.24%
Prev close $106.94
Market cap$12.5B
ConsensusStrong Buy
12-mo target$99.56 (-8.9%)
▲ Bullish
Analyst conviction 8/10
Insider Selling Cluster (3 insiders)32 New Institutional Positions18 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on HALO right now — valuation, ownership and activity at a glance.
Market Cap
$12.5B
Cap Size
Large Cap
Analyst Consensus
Strong Buy (81%)
Inst. Holders
50 funds
Inst. Value
$7.0B
Inst. Activity
32 buys / 18 sells
Insider Activity
$0.00 buy / $16.0M sell
Insider Net $
-$16.0M
Social Sentiment
36° Cool
SEC Reports
6
Price chart 30d -0.3%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 1, 2026 short_volume
Short Volume: HALO — 62.2% short (0.7M / 1.2M)
Short: 718,268 | Exempt: 3,969 | TRF Vol: 1,155,638 | Short Ratio: 62.2% | Off-exchange volume (dark
Sep 16, 2026 Insider
Posard Matthew L. sold 3,100 shares
Director @ $106.13 ($329.0K)
Sep 16, 2026 Insider
Posard Matthew L. sold 3,000 shares
Director @ $106.83 ($320.5K)
Sep 16, 2026 Insider
Posard Matthew L. sold 8,896 shares
Director @ $108.04 ($961.1K)
Aug 20, 2026 SEC
CEO Helen Torley executed a large-scale option exercise and open-market sale program over Aug 17-19, 2026, selling a tot
CLUSTER — Impact 2/10
Jul 10, 2026 SEC
CEO Helen Torley sold $153K in stock after exercising derivative shares at $12.07, netting a substantial cashless-settle
CLUSTER — Impact 2/10
Jul 3, 2026 SEC
Two HALO directors sold a combined $624K in open-market sales over a 3-day window, with the bulk ($548K) from Director K
CLUSTER — Impact 3/10
Jun 30, 2026 Inst.
LOS ANGELES CAPITAL MANAGEMENT — DOUBLED
1,938,035 shares ($151.7M)
Analyst ratings buy % +11.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Strong Buy 81% rate it Buy or better · 16 analysts
Strong Buy 3 19% Buy 10 63% Hold 3 19% Sell 0 0% Strong Sell 0 0%
Recent analyst actions
DateFirmActionRatingFirm rating
Sep 2, 2026HC Wainwright & Co.REITERATEBuy 43%
Aug 8, 2026Leerink PartnersUPGRADEOutperform 49%
Aug 7, 2026TD CowenMAINTAINBuy 56%
Aug 7, 2026CitizensMAINTAINMarket Outperform 38%
Aug 7, 2026Wells FargoMAINTAINEqual-Weight 54%
Aug 7, 2026HC Wainwright & Co.MAINTAINBuy 43%
Jul 21, 2026HC Wainwright & Co.REITERATEBuy 43%
May 12, 2026Morgan StanleyMAINTAINOverweight 55%
Apr 29, 2026HC Wainwright & Co.MAINTAINBuy 43%
Monthly consensus history
PeriodStr. BuyBuyHoldSellStr. SellBuy %Distribution
Sep 1, 202631030081%
Aug 1, 202621040075%
Jul 1, 20262941069%
Jun 1, 20262941069%
May 1, 20262931073%
Apr 1, 20262931073%
Mar 1, 20262931073%
Feb 1, 20262931073%
Price targets
Where 9 covering analysts think HALO trades over the next 12 months.
$99.56 -8.9% upside Sell
Current$109.34 Low$70.00 Median$105.00 High$115.00 9 analysts
$70.00$115.00
Analyst rating None as of Oct 2, 2026
Social media sentiment mood -9.1%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
36°
Cool
BearishNeutralBullish
3 mentions 0 bullish 2 bearish 1 neutral
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
6 SEC filing reports analyzed · 0 bullish, 0 bearish, 0 mixed, 6 neutral · avg impact 2.3/10.
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 1, 2026
short_volume
Short Volume: HALO — 62.2% short (0.7M / 1.2M)
Short: 718,268 | Exempt: 3,969 | TRF Vol: 1,155,638 | Short Ratio: 62.2% | Off-exchange volume (dark pool + OTC)
Sep 30, 2026
other
Halozyme Announces Appointment of Jim Daly to its Board of Directors
SAN DIEGO, Sept. 30, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced the appointment of
Sep 30, 2026
short_volume
Short Volume: HALO — 66.1% short (0.8M / 1.3M)
Short: 837,561 | Exempt: 190,749 | TRF Vol: 1,266,562 | Short Ratio: 66.1% | Off-exchange volume (dark pool + OTC)
Sep 28, 2026
short_volume
Short Volume: HALO — 69.8% short (0.6M / 0.8M)
Short: 579,843 | Exempt: 43,300 | TRF Vol: 830,219 | Short Ratio: 69.8% | Off-exchange volume (dark pool + OTC)
Sep 25, 2026
short_volume
Short Volume: HALO — 78.4% short (1.0M / 1.2M)
Short: 963,873 | Exempt: 24,710 | TRF Vol: 1,229,329 | Short Ratio: 78.4% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
PeriodEPS Est.RangeGrowth30d RevUp/DnRevenue#
Current Q$2.29$2.15–$2.3733.2%+0.0%2↑ 1↓$0.5B6
Next Q$2.59$2.43–$2.671179.6%+0.0%2↑ 1↓$0.5B6
Current FY$8.58$7.91–$8.90106.7%+0.0%2↑ 1↓$1.9B6
Next FY$10.39$10.00–$11.0121.2%+0.0%3↑ 1↓$2.1B5
Current-quarter EPS estimate — revision history
WhenEPS estimateChange vs now
Current$2.291—
7d ago$2.291—
30d ago$2.291—
60d ago$2.189+0.102
90d ago$2.189+0.102
Institutional ownership
Which big funds own HALO (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $7.0B total value (90,102,157 shares) as of 2026-Q2. Top holders: BlackRock,, VANGUARD, VANGUARD. Net buying activity: 32 institutions added/increased vs 18 reduced.
Top holders — 2026-Q2
FundSharesValue% TrackedLast move
BlackRock, Inc.13,271,095$1.0B14.8%—
VANGUARD CAPITAL MANAGEMENT LLC5,351,312$418.8M6.0%—
VANGUARD PORTFOLIO MANAGEMENT LLC5,299,008$414.8M5.9%—
STATE STREET CORP5,179,434$405.4M5.8%—
Invesco Ltd.3,177,997$248.7M3.5%—
MORGAN STANLEY2,832,594$221.7M3.2%—
Boston Partners2,773,568$216.8M3.1%—
BANK OF AMERICA CORP /DE/2,740,561$214.5M3.1%—
GEODE CAPITAL MANAGEMENT, LLC2,519,951$197.3M2.8%—
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC2,511,050$196.5M2.8%—
Recent position changes
FundActionPrevCurrentChangeValue
LOS ANGELES CAPITAL MANAGEMENT LLCDOUBLED689,9151,938,035+180.9%$151.7M
UBS Group AGADD914,0031,492,224+63.3%$116.8M
NORGES BANKNEW—1,483,648—$116.1M
GOLDMAN SACHS GROUP INCADD730,1401,270,344+74.0%$99.4M
Boston Trust Walden CorpADD679,5631,083,062+59.4%$84.8M
Assenagon Asset Management S.A.DOUBLED21,322997,643+4578.9%$78.1M
BNP PARIBAS FINANCIAL MARKETSADD338,291528,889+56.3%$41.4M
VICTORY CAPITAL MANAGEMENT INCADD355,099517,158+45.6%$40.5M
RENAISSANCE TECHNOLOGIES LLCTRIM731,811479,611-34.5%$37.5M
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLCTRIM528,031356,472-32.5%$27.9M
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
8 insiders, 50 transactions. Net -$16.0M — $0.00 bought, $16.0M sold.
DateInsiderTitleTypeSharesPriceValue
Sep 16, 2026Posard Matthew L.DirectorSELL3,100$106.13$329.0K
Sep 16, 2026Posard Matthew L.DirectorSELL3,000$106.83$320.5K
Sep 16, 2026Posard Matthew L.DirectorSELL8,896$108.04$961.1K
Sep 16, 2026Posard Matthew L.DirectorSELL4,000$108.99$436.0K
Sep 11, 2026Torley HelenPRESIDENT AND CEOEXERCISE20,000$18.41$368.2K
Sep 11, 2026Torley HelenPRESIDENT AND CEOSELL15,492$107.15$1.7M
Sep 11, 2026Torley HelenPRESIDENT AND CEOSELL4,508$107.55$484.8K
Sep 10, 2026Torley HelenPRESIDENT AND CEOEXERCISE20,000$18.41$368.2K
Sep 10, 2026Torley HelenPRESIDENT AND CEOSELL14,588$107.01$1.6M
Sep 10, 2026Torley HelenPRESIDENT AND CEOSELL5,412$107.58$582.2K
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for HALO.
Shares short
15,154,414
Settlement Sep 15, 2026
Change vs prior
+1.8%
Semi-monthly cycle
Days to cover
11.6
At avg daily volume
Of shares outstanding
≈13.3%
Estimate — not % of float
All HALO filing & press-release reports (6)